Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has demonstrated high anti-tumor activity in advanced-stage, metastatic castration-resistant prostate cancer (mCRPC) [1, 2]. Here, FOLH1 is linked to neoplasm.